Congress Should Not Impose Foreign Price Controls On Innovative Drugs
By: bitcoin ethereum news|2025/05/04 09:00:01
0
Share
VALUE and PRICE balancing Simple and neat solutions are alluring but often wrong. A case in point is President Trump’s proposal to adopt a most favored nation (MFN) policy. The MFN sets Medicaid’s price for a drug at the lowest price charged in other developed countries each of which has price controls on drugs. If implemented, this policy will make a bad situation much worse. The logic for implementing the MFN is simple – if patients in the U.K. or Canada are paying less money for a drug, then so should patients in the U.S. But the prices for innovative drugs in many OECD countries are only lower because these nations impose strict price controls, which always come with a high cost. To start with, price controls diminish drug availability. Thanks to price controls, patients in the other major industrialized countries (OECD) have access to only 29% of new medicines while patients in the U.S. have access to 85%. Even worse, patients in Canada and the U.K. can wait years for access to the latest treatments in some cases, and at any given time in Canada, there is a shortage of between 1,500 and 2,000 drugs. In those cases where the drugs are available in foreign nations, adopting the MFN policy outsources U.S. health policy to these countries. The U.S. should not impose price controls, but if it does, drug pricing decisions should not be outsourced to the EU, UK, or Canada. Adopting the MFN will also harm innovation. Developing a new drug takes a lot of time and money. On average, developing one innovative drug takes over $2.9 billion (including post-marketing expenditure) and between 10 and 15 years. It is also a risky endeavor. Approximately 9 out of every 10 drugs that reach the clinical trial stage will ultimately fail. Drug price controls make it harder for innovative firms to cover their capital costs, which reduces the amount of money spent on new innovations. A University of Chicago Issue Brief by Philipson and Durie found “that a 1 percent reduction in revenue leads to a 1.5 percent reduction in R&D activity.” The consequences from disincentivizing innovation would hit the U.S. economy hard. According to the latest industry economic impact report, the biotechnology industry directly contributed $1.4 trillion to the economy in 2023 (around 6.8% of the private sector GDP), supported nearly 2.3 million jobs, and paid hundreds of billions of dollars in taxes to the federal government. Perhaps even more important, the lost innovation from price controls harms patients currently living with diseases that have inadequate or no treatment options. If price controls are adopted in the U.S., then patients living with Alzheimer’s disease, pancreatic cancer, or muscular dystrophy may end up waiting in vain for efficacious treatments. Ultimately, the problem is that foreign governments are imposing price controls on drugs. The result is that patients across the globe benefit from American pharmaceutical innovation without paying their fair share of the innovation’s costs. The best way to address this problem is to defend the intellectual property of U.S. firms in trade negotiations. Executing on this goal could include appointing a pharmaceutical trade negotiator at USTR to defend American companies’ interests. Successfully concluding these negotiations is a long-term project, however. There are beneficial reforms that Congress can implement now that will promote greater drug availability in the meantime. These reforms should address the many inefficiencies that plague the U.S. drug market. For instance, more than half of the revenues from drug sales goes to hospitals, pharmacies, and other middlemen thanks to errant policies. These errant policies include the 340B drug discount program, which now has the contradictory impact of raising overall drug prices. Reforms should demand greater transparency in the program and mandate 340B only serves its intended population. These changes will improve 340B’s effectiveness while relieving the inflationary price pressures created by the program. Another necessary reform would address the current opaque drug pricing system that is empowering pharmacy benefit managers (PBMs) to the detriment of patients. Thanks to the system’s misaligned incentives, costs are being inequitably shifted to patients. Worsening the problem, the system often encourages the use of more expensive medicines rather than lower cost alternatives. Reining in PBMs will improve the drug market’s incentives resulting in lower out-of-pocket costs for patients without diminishing the incentives for innovation. The FDA approval process is also slow and overly burdensome. Reforming this process can lower the cost of developing new treatments while expediting their availability to patients. The goal of U.S. drug policy should be to promote the dual goals of innovation and broad-based affordability. The MFN policy adopts foreign imposed price controls that will discourage innovation and reduce patients access to medicines. While spending on medicine may go down, total healthcare spending is likely to increase as patients wind up requiring more expensive surgeries and hospital stays. Promoting more affordable drugs is not simple. It requires the hard work of understanding what is driving the problem and implementing policies that directly fix them. The MFN is a shortcut that patients will quickly come to regret. Source: https://www.forbes.com/sites/waynewinegarden/2025/05/03/congress-should-not-impose-foreign-price-controls-on-innovative-drugs/
You may also like

Polymarket vs. Kalshi: The Full Meme War Timeline
The topic itself has become a growth engine, and this "flame war" may be their most effective business strategy.

Consensus Check: What Consensus Was Born at the 2026 First Conference?
Just concluded in Hong Kong, Consensus HK 2026 has set the stage for a new narrative this year.

Resigned in Less Than a Year of Taking Office, Why Did Yet Another Key Figure at the Ethereum Foundation Depart?
The Ethereum Foundation once again finds itself at the crossroads of personnel turmoil.

Russian-Ukrainian War Prediction Market Analysis Report
By analyzing transaction patterns, validate the predictive market as a harbinger of truth in the new media order

Ethereum Foundation Executive Director Resigns, Coinbase Rating Downgrade: What's the Overseas Crypto Community Talking About Today?
What Have Foreigners Been Most Interested in the Last 24 Hours?

Who's at the CFTC Table? A Rebalancing of American Fintech Discourse
What on earth is the CFTC up to?
AI Trading vs Human Crypto Traders: $10,000 Live Trading Battle Results in Munich, Germany (WEEX Hackathon 2026)
Discover how AI trading outperformed human traders in WEEX's live Munich showdown. Learn 3 key strategies from the battle and why AI is changing crypto trading.
Elon Musk's X Money vs. Crypto's Synthetic Dollars: Who Wins the Future of Money?
How do Synthetic Dollars work? This guide explains their strategies, benefits over traditional stablecoins like USDT, and risks every crypto trader must know.

The Israeli military is hunting a mole on Polymarket
「The suspect's behavior has posed a significant operational risk and will be charged with serious security offenses.」

Q4 $667M Net Loss: Coinbase Earnings Report Foreshadows Challenging 2026 for Crypto Industry?
Coinbase reports $1.8B in total revenue in Q4 2025, with a $667M loss leading to a sharp drop in stock price.

BlackRock Buying UNI, What's the Catch?
DeFi has transitioned from "Experimental Finance" to "Infrastructure Finance."

Lost in Hong Kong
When yesterday's glory becomes today's shackles, only the courage to break free from the shackles can win tomorrow.

Gold Plunges Over 4%, Silver Crashes 11%, Stock Market Plummet Triggers Precious Metals Algorithmic Selling Pressure?
An analysis suggests that metal prices experienced a sudden drop due to a suspected algorithmic trading sell-off, leading some investors to unwind their positions in commodities including gold and silver to access liquidity.

Coinbase and Solana make successive moves, Agent economy to become the next big narrative
The new war around the Agent On-chain Economy has begun.

Aave DAO Wins, But the Game Is Not Over
The Aave community has achieved a milestone victory on the topics of revenue and governance, but key disagreements regarding the boundaries of funding, branding, and power remain unresolved

Coinbase Earnings Call, Latest Developments in Aave Tokenomics Debate, What's Trending in the Global Crypto Community Today?
What Was Trending Among Expats in the Last 24 Hours?

ICE, the parent company of the NYSE, Goes All In: Index Futures Contracts and Sentiment Prediction Market Tool
TradFi giants are moving into the crypto market at an unprecedented pace.

On-Chain Options: The Crossroads of DeFi Miners and Traders
An Insurance Policy, a Money Printer
Polymarket vs. Kalshi: The Full Meme War Timeline
The topic itself has become a growth engine, and this "flame war" may be their most effective business strategy.
Consensus Check: What Consensus Was Born at the 2026 First Conference?
Just concluded in Hong Kong, Consensus HK 2026 has set the stage for a new narrative this year.
Resigned in Less Than a Year of Taking Office, Why Did Yet Another Key Figure at the Ethereum Foundation Depart?
The Ethereum Foundation once again finds itself at the crossroads of personnel turmoil.
Russian-Ukrainian War Prediction Market Analysis Report
By analyzing transaction patterns, validate the predictive market as a harbinger of truth in the new media order
Ethereum Foundation Executive Director Resigns, Coinbase Rating Downgrade: What's the Overseas Crypto Community Talking About Today?
What Have Foreigners Been Most Interested in the Last 24 Hours?
Who's at the CFTC Table? A Rebalancing of American Fintech Discourse
What on earth is the CFTC up to?